RSV Vaccine Rules for Adults 50+: What's New for 2026

Quietly, in late February, the CDC moved the RSV vaccine age line down by ten years. The agency now recommends a single dose of RSV vaccine for all adults 75 and older, and for adults 50 to 74 who are at increased risk of severe RSV illness. That second part is the change worth paying attention to. If you're in your 50s or early 60s and you have diabetes, chronic lung disease, heart disease, or kidney trouble, this guidance now applies to you — even if your doctor hasn't brought it up yet. Here's what's actually new, what RSV does to older adults, and the practical question of whether you should ask about a shot before fall.

What Changed in the RSV Vaccine Guidance for 2026

Until February 2026, the CDC's adult RSV recommendation focused mainly on people 60 and older, with a shared clinical decision-making framework that left a lot of judgment calls to individual doctors. The updated guidance is clearer and broader. For adults 75 and up, the recommendation is now universal — every person in that age bracket should get one dose, full stop. For adults aged 50 to 74, the recommendation kicks in when you have one or more conditions that raise your RSV risk.

That second group is where most of the practical questions come up. The CDC's list of qualifying risk factors is specific: chronic lung disease (including COPD and asthma severe enough to need regular treatment), heart disease (especially congestive heart failure), diabetes with complications, chronic kidney or liver disease, weakened immune systems from disease or medication, and residence in a long-term care facility. Frailty and other chronic conditions that meaningfully increase severe respiratory infection risk also qualify.

If any of those describe you, the new rules say the vaccine is recommended — not optional, not a "talk to your doctor about whether you might want this." It's a yes.

Why RSV Is a Bigger Deal Than Most People Realize

Most adults under 60 think of RSV, if they think of it at all, as a kids' illness — the virus that causes coughs and ear infections in toddlers. That framing is dangerously outdated for our age group. The CDC estimates that RSV hospitalizes between 110,000 and 180,000 adults aged 65 and older each year in the United States, with tens of thousands of additional hospitalizations in the 50-to-64 age range.

The hospitalization rate climbs sharply with age. CDC surveillance data shows roughly 67 RSV hospitalizations per 100,000 adults aged 50 to 64, compared to 178 per 100,000 for adults 65 and older. Among hospitalized older adults, RSV produces outcomes that look broadly similar to influenza — and that's not a comforting comparison, because flu kills tens of thousands of older Americans every year.

There's also a quieter complication that's drawn more research attention recently. A study published in PMC found that cardiovascular events occurred in 18.5% of patients hospitalized for RSV — heart attacks, strokes, new arrhythmias, and worsening heart failure all showed up at meaningfully higher rates in the weeks following an RSV hospitalization. If you already have a heart condition, RSV isn't just a respiratory problem. It's a cardiovascular stressor.

Which Vaccine, and Does It Matter

Three RSV vaccines are FDA-licensed and recommended for adults 50 and older: GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mResvia. The CDC explicitly states that there is no preference among them — get whichever your pharmacy or doctor has in stock. All three are single-dose, all three have been studied in large clinical trials, and all three produce strong protection against severe RSV outcomes.

The most useful detail to know: this is not an annual vaccine. One dose provides protection for at least two years, and likely longer. If you got an RSV shot in 2024 or 2025, you do not need another one this year. The CDC is currently studying whether revaccination will ever be needed and, if so, on what schedule.

Cost should not be a barrier for most older adults. Medicare Part D covers RSV vaccines with no out-of-pocket cost, and most private insurance plans cover them as a preventive service. Pharmacy chains and primary care offices generally stock at least one of the three options.

The Timing Question Nobody Asks About

Here's a piece of practical advice that doesn't get nearly enough attention: when you get the RSV vaccine matters almost as much as whether. RSV is seasonal in the United States, with most cases occurring between late fall and early spring. Protection from the vaccine ramps up over a couple of weeks after the shot. The CDC's recommendation is to aim for August through October in most of the continental U.S., so antibody levels are high heading into the worst of the season.

That makes mid-to-late summer the sweet spot. May — right now — is when to start thinking about it and to schedule. Don't wait until you're already coughing and wondering whether what you have is RSV, the flu, or just a cold. The vaccine doesn't help once you're sick; it helps before exposure.

If you're traveling internationally during the summer, ask your doctor about timing earlier. RSV seasons run differently in the Southern Hemisphere and in tropical regions, and what feels like the off-season here may be peak transmission somewhere else.

Side Effects, Honestly

The most common reactions to RSV vaccines are the same as most adult shots: sore arm, fatigue for a day or two, sometimes a mild headache or muscle ache. Serious side effects are rare. The most-discussed concern has been a small possible signal for Guillain-Barré syndrome — a rare neurological condition — in some post-marketing surveillance data, particularly for Abrysvo and Arexvy. The CDC reviewed that signal in detail and concluded that the benefits of vaccination substantially outweigh the very small theoretical risk in the recommended age groups.

If you have a personal history of Guillain-Barré syndrome, mention it to your doctor before vaccination. For most people, the practical risk-benefit calculation is straightforward: a sore arm versus a meaningfully lower chance of being hospitalized with a respiratory infection that could also tip a heart condition into crisis.

What to Actually Do in May 2026

If you're 50 or older with any of the qualifying conditions — diabetes, COPD, heart failure, kidney disease, an immune-suppressing medication — bring up the RSV vaccine at your next medical appointment. If you don't have an appointment soon, it's worth calling your primary care office or pharmacist directly to ask. Plenty of pharmacies administer RSV vaccines without requiring a doctor's visit, especially for adults 75 and over where the recommendation is universal.

If you're 75 or older and haven't been vaccinated, the conversation is even simpler: this is a recommended preventive shot for everyone in your age group. The vaccine is at your pharmacy. Walk in or call to schedule.

One small practical layer worth adding: write the vaccination date down somewhere you'll find it later. Because RSV vaccines aren't annual, two or three years from now you'll genuinely want to remember when you got yours, and "sometime around 2026" doesn't help your future doctor. SteadiDay's free Calendar sync feature is one easy way to log the date and the vaccine name — the entry shows up alongside everything else you're tracking, and you'll have it when the next conversation about boosters comes around.

The Bottom Line on RSV Vaccination in 2026

The big shift this year is that the CDC stopped treating RSV protection as something to negotiate case-by-case and started treating it as a recommended part of adult preventive care for two clear groups: everyone 75 and up, and adults 50 to 74 with conditions that raise their risk. One dose. Three vaccine options, no preferred brand. Lasts at least two years. Best timed for late summer or early fall. Most adults pay nothing.

If you fit either group, the next step is a phone call — to your doctor, your pharmacist, or your insurance plan to confirm coverage. Five minutes of effort now means one less thing to worry about when the first cold front of the season rolls through.